4th International LFS Association Symposium | 2018 | Day 1 - Li-Fraumeni Syndrome Association

Opening Remarks:

Dr. David Malkin

Jamie Higgins and Cameron Block
“Patient Perspectives”

Dr. Robert Lufkin
Variant LFS phenotypes in Brazil: new insights into variant pathogenicity

Jenn Perry, LFS Association President

Keynote Address: Prof. Sir David Lane
Mutant p53: regulation of expression in normal tissues and in tumours

Dr. Joshua Schiffman
Exploring elephant p53 (EP53) as a mechanism for cancer resistance

Prof. David Langenau
Fishing for insights into LFS using p53-deficient zebrafish

Dr. Jason Berman
Fishing for clues: preventing disease progression in cancer predisposition syndromes using zebrafish

Dr. Gerry Zambetti
The hypomorphic Brazilian mutant TP53-R337H and variable tumor susceptibility: identification of a genetic modifier

Dr. Adam Shlien
Signatures and timing of mutations in sporadic and inherited childhood cancers

Mr. Ben Brew
Using methylation to predict early cancer onset in patients with Li-Fraumeni syndrome

Prof. David Thomas
Whole genome analysis of 1141 patients with sarcoma: Li-Fraumeni syndrome and beyond

Dr. Wenyi Wang
Cancer risk assessment and penetrance estimation for deleterious mutations in TP53 using a multi-centre consortium

Prof. Gareth Bond
Common genetic variants in p53 pathway affect cancer risk in the general population and LFS families, but could benefit cancer management strategies

Prof. Gigi Lozano
Mutant p53 activities in tumor development

Prof. Carol Prives
Are the opposite roles of wild-type and mutant p53 regulation of the mevalonate pathway relevant to treatment options for LFS patients?